The effect of mepolizumab dosage form on treatment outcomes in
severe asthma

J 2025

The effect of mepolizumab dosage form on treatment outcomes in severe asthma

VETCHÁ, Martina; Kateřina KUBOVÁ; Constantinos GLYNOS; Sylvie PAVLOKOVÁ; Irena KRČMOVÁ et al.

Základní údaje

Originální název

The effect of mepolizumab dosage form on treatment outcomes in severe asthma

Autoři

VETCHÁ, Martina; Kateřina KUBOVÁ ; Constantinos GLYNOS; Sylvie PAVLOKOVÁ ; Irena KRČMOVÁ; Eva VOLÁKOVÁ; Ondřej FIBIGR; Beáta HUTYROVÁ; Alena VLACHOVÁ; Jiří ZEMAN a David VETCHÝ

Vydání

FRONTIERS IN MEDICINE, SWITZERLAND, FRONTIERS MEDIA SA, 2025, 2296-858X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.000 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14160/25:00141057

Organizační jednotka

Farmaceutická fakulta

Klíčová slova anglicky

parenteral dosage form; lyophilized injection; autoinjector; syringe; homecare; severe asthma; monoclonal antibody; mepolizumab

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 4. 2026 09:27, Mgr. Irena Doubková

Anotace

V originále

A monoclonal antibody such as mepolizumab typically first appears as a parenteral lyophilized formulation (LYO), then as various parenteral solution forms, and finally as a self-administered form at homecare. While more studies compare mepolizumab safety and efficacy across dosage forms, no data exists on the impact of switching to more successive dosage forms in real-world settings. This study aims to assess clinical outcomes in patients from five national Czech asthma centers who were switched from the LYO to the liquid formulation and then to home self-administration. Methods: Mepolizumab was administered in three phases: LYO for 6–9 months, followed by prefilled syringes (PFS) or autoinjectors (AI) in hospitals for 6–9 months, and finally, liquid forms at homecare for another 6–9 months. Data collected included age, BMI, nasal polyposis (NP), gastroesophageal reflux (GERD), and other comorbidities. The results were statistically evaluated using exacerbation rate (ER), asthma control test, forced expiratory volume, blood eosinophil count, and required systemic oral corticosteroid (OCS) daily dose. Results: Three months after initiation of administration, all methods showed improvement compared to the values at the beginning of treatment, with ER decreasing from a median of 4 to 0. Similarly, the median OCS decreased from 5 mg to 0 mg across all methods throughout the treatment. A more significant OCS dose reduction was observed in patients with NP (87.5% vs. 50%) and GERD (70% vs. 50%), who typically require higher OCS doses to achieve asthma control. AI/PFS outperformed LYO in ER (97.5–100% vs. 50–100% after 6–9 months of treatment) and OCS reduction (50–100% vs. 31.2–100% after 6–9 months of treatment), which was influenced rather by the later usage of AI/PFS and thus longer overall treatment times than the administrating method. Conclusion: Mepolizumab improved real-life clinical outcomes in patients with severe asthma, regardless of the dosage forms or homecare settings.

Citovat

VETCHÁ, Martina; Kateřina KUBOVÁ; Constantinos GLYNOS; Sylvie PAVLOKOVÁ; Irena KRČMOVÁ; Eva VOLÁKOVÁ; Ondřej FIBIGR; Beáta HUTYROVÁ; Alena VLACHOVÁ; Jiří ZEMAN a David VETCHÝ. The effect of mepolizumab dosage form on treatment outcomes in severe asthma. FRONTIERS IN MEDICINE. SWITZERLAND: FRONTIERS MEDIA SA, 2025, roč. 12, č. 12, s. 1-9. ISSN 2296-858X. Dostupné z: https://doi.org/10.3389/fmed.2025.1537074.

@article{2492621,
   author = {Vetchá, Martina and Kubová, Kateřina and Glynos, Constantinos and Pavloková, Sylvie and Krčmová, Irena and Voláková, Eva and Fibigr, Ondřej and Hutyrová, Beáta and Vlachová, Alena and Zeman, Jiří and Vetchý, David},
   article_location = {SWITZERLAND},
   article_number = {12},
   doi = {https://doi.org/10.3389/fmed.2025.1537074},
   keywords = {parenteral dosage form; lyophilized injection; autoinjector; syringe; homecare; severe asthma; monoclonal antibody; mepolizumab},
   language = {eng},
   issn = {2296-858X},
   journal = {FRONTIERS IN MEDICINE},
   title = {The effect of mepolizumab dosage form on treatment outcomes in severe asthma},
   url = {https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1537074/full},
   volume = {12},
   year = {2025}
}

TY  - JOUR
ID  - 2492621
AU  - Vetchá, Martina - Kubová, Kateřina - Glynos, Constantinos - Pavloková, Sylvie - Krčmová, Irena - Voláková, Eva - Fibigr, Ondřej - Hutyrová, Beáta - Vlachová, Alena - Zeman, Jiří - Vetchý, David
PY  - 2025
TI  - The effect of mepolizumab dosage form on treatment outcomes in severe asthma
JF  - FRONTIERS IN MEDICINE
VL  - 12
IS  - 12
SP  - 1-9
EP  - 1-9
PB  - FRONTIERS MEDIA SA
SN  - 2296858X
KW  - parenteral dosage form
KW  - lyophilized injection
KW  - autoinjector
KW  - syringe
KW  - homecare
KW  - severe asthma
KW  - monoclonal antibody
KW  - mepolizumab
UR  - https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1537074/full
N2  - A monoclonal antibody such as mepolizumab typically first appears as a parenteral lyophilized formulation (LYO), then as various parenteral solution forms, and finally as a self-administered form at homecare. While more studies compare mepolizumab safety and efficacy across dosage forms, no data exists on the impact of switching to more successive dosage forms in real-world settings. This study aims to assess clinical outcomes in patients from five national Czech asthma centers who were switched from the LYO to the liquid formulation and then to home self-administration. Methods: Mepolizumab was administered in three phases: LYO for 6–9 months, followed by prefilled syringes (PFS) or autoinjectors (AI) in hospitals for 6–9 months, and finally, liquid forms at homecare for another 6–9 months. Data collected included age, BMI, nasal polyposis (NP), gastroesophageal reflux (GERD), and other comorbidities. The results were statistically evaluated using exacerbation rate (ER), asthma control test, forced expiratory volume, blood eosinophil count, and required systemic oral corticosteroid (OCS) daily dose. Results: Three months after initiation of administration, all methods showed improvement compared to the values at the beginning of treatment, with ER decreasing from a median of 4 to 0. Similarly, the median OCS decreased from 5 mg to 0 mg across all methods throughout the treatment. A more significant OCS dose reduction was observed in patients with NP (87.5% vs. 50%) and GERD (70% vs. 50%), who typically require higher OCS doses to achieve asthma control. AI/PFS outperformed LYO in ER (97.5–100% vs. 50–100% after 6–9 months of treatment) and OCS reduction (50–100% vs. 31.2–100% after 6–9 months of treatment), which was influenced rather by the later usage of AI/PFS and thus longer overall treatment times than the administrating method. Conclusion: Mepolizumab improved real-life clinical outcomes in patients with severe asthma, regardless of the dosage forms or homecare settings.
ER  -

VETCHÁ, Martina; Kateřina KUBOVÁ; Constantinos GLYNOS; Sylvie PAVLOKOVÁ; Irena KRČMOVÁ; Eva VOLÁKOVÁ; Ondřej FIBIGR; Beáta HUTYROVÁ; Alena VLACHOVÁ; Jiří ZEMAN a David VETCHÝ. The effect of mepolizumab dosage form on treatment outcomes in severe asthma. \textit{FRONTIERS IN MEDICINE}. SWITZERLAND: FRONTIERS MEDIA SA, 2025, roč.~12, č.~12, s.~1-9. ISSN~2296-858X. Dostupné z: https://doi.org/10.3389/fmed.2025.1537074.

Přehled o publikaci